A Design of Experiments for Tablet Compression - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Design of Experiments for Tablet Compression
The author prepared and analyzed a detailed design of experiments for the manufacture of a simple tablet formulation. The aim was to test whether tablet hardness and weight could be controlled during the compression process by adjusting certain machine parameters.


Pharmaceutical Technology
Volume 35, Issue 9


Figure 4: Half-normal plot of tablet weight.
Weight response. Tablet weight is a crucial tablet characteristic, and data analysis is necessary for this response. The half-normal plot for tablet weight using the original screening results is shown in Figure 4. The plot indicates that factors A, B, C, and E significantly affected the weight response. The analysis of variance shown in Table VI supports the plot in Figure 4.

In the next equation, R 2 is 0.9955, adjusted R 2 is 0.9945, and adequate precision is 126.423. The R 2 of 0.9955 is in reasonable agreement with the adjusted R 2 of 0.9945. The adequate precision ratio of 126.423 indicates an adequate signal, so the following equation, in terms of coded factors, can be used to establish the design space:





Figure 5: Normal plot of residuals for weight.
The 95% confidence intervals for the coefficients of each of the significant terms were verified to exclude zero, which supports the determination that all identified factors in the model equation influence the response. A normal plot of residuals was constructed to determine whether the distribution was normal (see Figure 5).


Figure 6: Residuals versus predicted plot for weight.
A residuals versus predicted plot was constructed to look for trends in the data (see Figure 6). All data points are equally distributed and are within two standard deviations from the mean, with two exceptions. One high point is 2.422 standard deviations, and one low point is –2.473 standard deviations). The two data points that lie beyond 2 standard deviations of the mean could be investigated, and these experiments may warrant being rerun to confirm the data response. The data have no potential outliers.


Appendix Figure 5: One-factor plot, tablet weight versus fill-cam height.
No two-factor interactions can be plotted, though factor E (i.e., fill-cam height and weight-adjustment ramp) had a significant effect on tablet weight. As can be expected, the amount of powder placed into the die cavity had a direct effect on tablet weight. This is clearly evident in Appendix Figure 5. The plot shows that as the weight ramp or fill cam height is increased, tablet weight increases.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here